Antibody-dependent effector functions against HIV decline in subjects receiving antiretroviral therapy.

BACKGROUND Combination antiretroviral therapy (cART) effectively controls human immunodeficiency virus (HIV) infection but does not eliminate HIV, and lifelong treatment is therefore required. HIV-specific cytotoxic T lymphocyte (CTL) responses decline following cART initiation. Alterations in other HIV-specific immune responses that may assist in eliminating latent HIV infection, specifically antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent phagocytosis (ADP), are unclear. METHODS A cohort of 49 cART-naive HIV-infected subjects from Thailand (mean baseline CD4 count, 188 cells/µL; mean viral load, 5.4 log10 copies/mL) was followed for 96 weeks after initiating cART. ADCC and ADP assays were performed using serum samples obtained at baseline and after 96 weeks of cART. RESULTS A 35% reduction in HIV type 1 envelope (Env)-specific ADCC-mediated killing of target cells (P<.001) was observed after 96 weeks of cART. This was corroborated by a significant reduction in the ability of Env-specific ADCC antibodies to activate natural killer cells (P<.001). Significantly reduced ADP was also observed after 96 weeks of cART (P=.018). CONCLUSIONS This longitudinal study showed that cART resulted in significant reductions of HIV-specific effector antibody responses, including ADCC and ADP. Therapeutic vaccines or other immunomodulatory approaches may be required to improve antibody-mediated control of HIV during cART.

[1]  Jerome H. Kim,et al.  HIV‐specific antibody‐dependent phagocytosis matures during HIV infection , 2014, Immunology and cell biology.

[2]  J. Ananworanich,et al.  Incomplete restoration of Mycobacterium tuberculosis-specific-CD4 T cell responses despite antiretroviral therapy. , 2014, The Journal of infection.

[3]  Jerome H. Kim,et al.  Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys , 2013, Cell.

[4]  J. Ananworanich,et al.  Restoration of CMV-Specific-CD4 T Cells with ART Occurs Early and Is Greater in Those with More Advanced Immunodeficiency , 2013, PloS one.

[5]  S. Lewin,et al.  The search for an HIV cure: tackling latent infection. , 2013, The Lancet. Infectious diseases.

[6]  R. Siliciano,et al.  From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication. , 2013, BioEssays : news and reviews in molecular, cellular and developmental biology.

[7]  Angus P R Johnston,et al.  A programmable sensor to probe the internalization of proteins and nanoparticles in live cells. , 2013, Angewandte Chemie.

[8]  Jerome H. Kim,et al.  Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG , 2013, Proceedings of the National Academy of Sciences.

[9]  R. Center,et al.  Role of monocytes in mediating HIV-specific antibody-dependent cellular cytotoxicity. , 2012, Journal of immunological methods.

[10]  A. Trkola,et al.  ADCC Develops Over Time during Persistent Infection with Live-Attenuated SIV and Is Associated with Complete Protection against SIVmac251 Challenge , 2012, PLoS pathogens.

[11]  J. Eron,et al.  Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy , 2012, Nature.

[12]  M. Lederman,et al.  Towards an HIV cure: a global scientific strategy , 2012, Nature Reviews Immunology.

[13]  R. Center,et al.  Influence of Cytokines on HIV-Specific Antibody-Dependent Cellular Cytotoxicity Activation Profile of Natural Killer Cells , 2012, PloS one.

[14]  A. Maisa,et al.  HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy , 2012, AIDS.

[15]  Guido Ferrari,et al.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial. , 2012, The New England journal of medicine.

[16]  R. Siliciano,et al.  Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. , 2012, Immunity.

[17]  A. Lafeuillade.  Eliminating the HIV Reservoir , 2012, Current HIV/AIDS Reports.

[18]  G. Alter,et al.  Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals. , 2011, Virology.

[19]  J. Kublin,et al.  Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. , 2011, The Lancet. Infectious diseases.

[20]  D. Irvine,et al.  A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. , 2010, Journal of immunological methods.

[21]  G. Stewart,et al.  Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation. , 2010, The Journal of infectious diseases.

[22]  A. Kelleher,et al.  Vaccine-induced IgG2 anti-HIV p24 is associated with control of HIV in patients with a ‘high-affinity’ FcγRIIa genotype , 2010, AIDS.

[23]  Sudhir Gupta,et al.  Impaired Functions of Peripheral Blood Monocyte Subpopulations in Aged Humans , 2010, Journal of Clinical Immunology.

[24]  E. Thiel,et al.  Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. , 2009, The New England journal of medicine.

[25]  S. Alcântara,et al.  Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. , 2009, Vaccine.

[26]  R. Center,et al.  Rapid Degranulation of NK Cells following Activation by HIV-Specific Antibodies1 , 2009, The Journal of Immunology.

[27]  Devan V Mehrotra,et al.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial , 2008, The Lancet.

[28]  S. Kent,et al.  Robust NK Cell-Mediated Human Immunodeficiency Virus (HIV)-Specific Antibody-Dependent Responses in HIV-Infected Subjects , 2008, Journal of Virology.

[29]  D. Burton,et al.  Fc receptor but not complement binding is important in antibody protection against HIV , 2007, Nature.

[30]  A. Trkola,et al.  Humoral immunity to HIV‐1: neutralization and beyond , 2007, Journal of internal medicine.

[31]  M. Battegay,et al.  Immunological recovery and antiretroviral therapy in HIV-1 infection. , 2006, The Lancet. Infectious diseases.

[32]  J. Hocking,et al.  Normal CD16 expression and phagocytosis of Mycobacterium avium complex by monocytes from a current cohort of HIV-1-infected patients. , 2006, The Journal of infectious diseases.

[33]  D. Venzon,et al.  A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. , 2006, Journal of immunological methods.

[34]  J. Reece,et al.  Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques. , 2005, Vaccine.

[35]  D. Venzon,et al.  Vaccine-Elicited Antibodies Mediate Antibody-Dependent Cellular Cytotoxicity Correlated with Significantly Reduced Acute Viremia in Rhesus Macaques Challenged with SIVmac2511 , 2005, The Journal of Immunology.

[36]  B. Moss,et al.  Promoting Trimerization of Soluble Human Immunodeficiency Virus Type 1 (HIV-1) Env through the Use of HIV-1/Simian Immunodeficiency Virus Chimeras , 2004, Journal of Virology.

[37]  D. Katzenstein,et al.  Characterization of the HIV‐1 Specific Humoral Immune Response During Highly Active Antiretroviral Therapy (HAART) , 2001, Journal of acquired immune deficiency syndromes.

[38]  J. Goudsmit,et al.  Potent antiretroviral therapy initiates normalization of hypergammaglobulinemia and a decline in HIV type 1-specific antibody responses. , 2001, AIDS research and human retroviruses.

[39]  R. Koup,et al.  Decay Kinetics of Human Immunodeficiency Virus-Specific CD8+ T Cells in Peripheral Blood after Initiation of Highly Active Antiretroviral Therapy , 2001, Journal of Virology.

[40]  D. Ho,et al.  HIV-1 Antigen–specific and –nonspecific B Cell Responses Are Sensitive to Combination Antiretroviral Therapy , 1998, The Journal of experimental medicine.

[41]  M. McGrath,et al.  Unique monocyte subset in patients with AIDS dementia , 1997, The Lancet.

[42]  J. Margolick,et al.  HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. , 1996, Journal of immunology.

[43]  C. Estcourt,et al.  CD14lowCD16high: A cytokine‐producing monocyte subset which expands during human immunodeficiency virus infection , 1995, European journal of immunology.

[44]  G. Vanham,et al.  Expression patterns of Fcγ receptors, HLA‐DR and selected adhesion molecules on monocytes from normal and HIV‐infected individuals , 1994, Clinical and experimental immunology.

[45]  C. Zanussi,et al.  Increased expression of IgG Fc receptor type I on neutrophils and monocytes from HIV‐infected subjects , 1992, Clinical and experimental immunology.